Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: A representative study

M. Holodniy, E. D. Charlebois, David Bangsberg, A. R. Zolopa, M. Schulte, A. R. Moss

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We determined the prevalence of antiretroviral (ARV) resistance in HIV-1 infected indigent persons in San Francisco, California. Three hundred and twenty-seven subjects (159 (49%) ARV naïve, and 168 (51%) ARV-experienced), were recruited during 1996-97 and 1999-2000. Plasma HIV-1 viral load quantification and genotypic resistance testing were performed. Twice as many subjects received nucleoside reverse transcriptase inhibitors (NRTIs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs); resistance mutation prevalences were 30%, 14% and 16% respectively. Risk of any resistance mutations was strongly and independently associated with prior ARV exposure (OR = 1.3 per year of exposure, P < 0.0001) and with ARV exposure prior to HAART (OR = 2.5, P = 0.015). Prevalences of primary ARV resistance mutations among both treatment-naive and treatment-experienced subjects in this indigent urban population are low compared to other observational cohorts, are directly related to length and type of prior ARV exposure, and did not increase significantly between recruitment periods.

Original languageEnglish (US)
Pages (from-to)543-551
Number of pages9
JournalInternational Journal of STD and AIDS
Volume15
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Urban Population
San Francisco
Poverty
Drug Resistance
HIV-1
Reverse Transcriptase Inhibitors
Mutation
Highly Active Antiretroviral Therapy
Protease Inhibitors
Viral Load
Nucleosides
Therapeutics

Keywords

  • Antiretroviral therapy
  • HIV
  • Homeless
  • Prevalence
  • Resistance

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Immunology

Cite this

Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco : A representative study. / Holodniy, M.; Charlebois, E. D.; Bangsberg, David; Zolopa, A. R.; Schulte, M.; Moss, A. R.

In: International Journal of STD and AIDS, Vol. 15, No. 8, 08.2004, p. 543-551.

Research output: Contribution to journalArticle

@article{de32fbd35a934b8c953cff935d7bd3cb,
title = "Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: A representative study",
abstract = "We determined the prevalence of antiretroviral (ARV) resistance in HIV-1 infected indigent persons in San Francisco, California. Three hundred and twenty-seven subjects (159 (49{\%}) ARV na{\"i}ve, and 168 (51{\%}) ARV-experienced), were recruited during 1996-97 and 1999-2000. Plasma HIV-1 viral load quantification and genotypic resistance testing were performed. Twice as many subjects received nucleoside reverse transcriptase inhibitors (NRTIs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs); resistance mutation prevalences were 30{\%}, 14{\%} and 16{\%} respectively. Risk of any resistance mutations was strongly and independently associated with prior ARV exposure (OR = 1.3 per year of exposure, P < 0.0001) and with ARV exposure prior to HAART (OR = 2.5, P = 0.015). Prevalences of primary ARV resistance mutations among both treatment-naive and treatment-experienced subjects in this indigent urban population are low compared to other observational cohorts, are directly related to length and type of prior ARV exposure, and did not increase significantly between recruitment periods.",
keywords = "Antiretroviral therapy, HIV, Homeless, Prevalence, Resistance",
author = "M. Holodniy and Charlebois, {E. D.} and David Bangsberg and Zolopa, {A. R.} and M. Schulte and Moss, {A. R.}",
year = "2004",
month = "8",
doi = "10.1258/0956462041558212",
language = "English (US)",
volume = "15",
pages = "543--551",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco

T2 - A representative study

AU - Holodniy, M.

AU - Charlebois, E. D.

AU - Bangsberg, David

AU - Zolopa, A. R.

AU - Schulte, M.

AU - Moss, A. R.

PY - 2004/8

Y1 - 2004/8

N2 - We determined the prevalence of antiretroviral (ARV) resistance in HIV-1 infected indigent persons in San Francisco, California. Three hundred and twenty-seven subjects (159 (49%) ARV naïve, and 168 (51%) ARV-experienced), were recruited during 1996-97 and 1999-2000. Plasma HIV-1 viral load quantification and genotypic resistance testing were performed. Twice as many subjects received nucleoside reverse transcriptase inhibitors (NRTIs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs); resistance mutation prevalences were 30%, 14% and 16% respectively. Risk of any resistance mutations was strongly and independently associated with prior ARV exposure (OR = 1.3 per year of exposure, P < 0.0001) and with ARV exposure prior to HAART (OR = 2.5, P = 0.015). Prevalences of primary ARV resistance mutations among both treatment-naive and treatment-experienced subjects in this indigent urban population are low compared to other observational cohorts, are directly related to length and type of prior ARV exposure, and did not increase significantly between recruitment periods.

AB - We determined the prevalence of antiretroviral (ARV) resistance in HIV-1 infected indigent persons in San Francisco, California. Three hundred and twenty-seven subjects (159 (49%) ARV naïve, and 168 (51%) ARV-experienced), were recruited during 1996-97 and 1999-2000. Plasma HIV-1 viral load quantification and genotypic resistance testing were performed. Twice as many subjects received nucleoside reverse transcriptase inhibitors (NRTIs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs); resistance mutation prevalences were 30%, 14% and 16% respectively. Risk of any resistance mutations was strongly and independently associated with prior ARV exposure (OR = 1.3 per year of exposure, P < 0.0001) and with ARV exposure prior to HAART (OR = 2.5, P = 0.015). Prevalences of primary ARV resistance mutations among both treatment-naive and treatment-experienced subjects in this indigent urban population are low compared to other observational cohorts, are directly related to length and type of prior ARV exposure, and did not increase significantly between recruitment periods.

KW - Antiretroviral therapy

KW - HIV

KW - Homeless

KW - Prevalence

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=4344636326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344636326&partnerID=8YFLogxK

U2 - 10.1258/0956462041558212

DO - 10.1258/0956462041558212

M3 - Article

C2 - 15307966

AN - SCOPUS:4344636326

VL - 15

SP - 543

EP - 551

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 8

ER -